Last Updated: September 24, 2026

Details for New Drug Application (NDA): 203284

✉ Email this page to a colleague

NDA 203284 describes RAVICTI, which is a drug marketed by Horizon Therap Us and is included in one NDA. It is available from two suppliers. There are fourteen patents protecting this drug and one Paragraph IV challenge. Additional details are available on the RAVICTI profile page.

The generic ingredient in RAVICTI is glycerol phenylbutyrate. There is one drug master file entry for this compound. Nine suppliers are listed for this compound. Additional details are available on the glycerol phenylbutyrate profile page.

Summary for 203284

Tradename:	RAVICTI
Applicant:	Horizon Therap Us
Ingredient:	glycerol phenylbutyrate
Patents:	14

Pharmacology for NDA: 203284

Mechanism of Action	Ammonium Ion Binding Activity

Medical Subject Heading (MeSH) Categories for 203284

Cryoprotective Agents
Solvents

Suppliers and Packaging for NDA: 203284

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
RAVICTI	glycerol phenylbutyrate	LIQUID;ORAL	203284	NDA	Lupin Pharmaceuticals, Inc.	70748-425	70748-425-01	1 BOTTLE in 1 CARTON (70748-425-01) / 25 mL in 1 BOTTLE
RAVICTI	glycerol phenylbutyrate	LIQUID;ORAL	203284	NDA	Horizon Therapeutics USA, Inc.	75987-050	75987-050-06	1 BOTTLE in 1 CARTON (75987-050-06) / 25 mL in 1 BOTTLE

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	LIQUID;ORAL			Strength	1.1GM/ML
Approval Date:	Feb 1, 2013	TE:	AA	RLD:	Yes
Patent:	10,045,958	Patent Expiration:	Sep 22, 2030	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	TREATMENT OF A UREA CYCLE DISORDER
Patent:	10,045,959	Patent Expiration:	Sep 22, 2030	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	TREATMENT OF A UREA CYCLE DISORDER
Patent:	10,183,002	Patent Expiration:	Sep 22, 2030	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	TREATMENT OF A UREA CYCLE DISORDER

Expired US Patents for NDA 203284

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Horizon Therap Us	RAVICTI	glycerol phenylbutyrate	LIQUID;ORAL	203284-001	Feb 1, 2013	5,968,979	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.